anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Purpose: Drownings are a societal phenomenon occurring worldwide, hence the importance of rescue skills, including directly towing a victim to a safe place. The purpose of this study was to evaluate the most effective towing techniques based on kinematic parameters, considering different types of drowning cases, for their recommendation for widespread use in water rescue. Methods: The research involved 18 water lifeguards aged 18-25 years. The evaluation included speed tests in towing a mannequin over a distance of 50 m using the Extended Arm Tow (EAT), Double Armpit Tow (DAT), "Sailor" Technique Tow (STT) and with a rescue tube (RT), accompanied by video recording to measure in the designated measurement area the number of cyclic paddling movements by the lower limbs, angles of the body attack, towing velocity, and its decrease during towing. Results: Number of cyclic paddling movements by the lower limbs, towing with a RT was considered the most beneficial, and least beneficial was the DAT. In the DAT, the lifeguard swam with the smallest body angle, in contrast to the STT, where this angle was the largest. The effect of the number of cyclic paddling movements and the body angle by the lifeguard was the velocity, with the highest value recorded in towing using a RT; in other techniques, velocity were similar. Conclusions: Institutions associated with water rescue should recommend towing using a RT for direct rescue actions in the water, as its use shortens the time, while simultaneously increasing safety for both the rescuer and the victim.
This study is a prospective, three-arm, randomized controlled trial of neuromodulatory treatments for chronic pain, for post-9/11 veterans with co-occuring pain and TBI. Three hundred participants will be scheduled for a baseline interview at the Duke Behavioral Health and Technology Lab after passing a preliminary telephone screen. After providing informed consent, participants will provide data on clinical measures. Electroencephalography (EEG) will be used to measure brain activity. Following data collection, participants will be assigned to one of three groups (n=100 in each). Each group will receive an iPod Touch with a different mobile application (app), which participants will be instructed to use for 10 minute a day, 4 times a week for 12 weeks. Study coordinators will conduct two home visits (week 1 and week 6) and two phone calls (week 3 and week 9) to reinforce training, troubleshoot difficulties, and ask about intervention utilization. Follow-up data on clinical measures and EEG will be collected at 12 weeks and again at 24 weeks.
Provided are a similar medical case search device, a similar medical case search method, and a similar medical case search program, with which the feature amounts of multiple regions of interest are taken into account in an integrated manner. A similar medical case search server (17) is equipped with a feature amount calculation unit (62), an individual similarity calculation unit (65), and a similar medical case search unit (67). The feature amount calculation unit (62) obtains a feature amount for each of multiple regions of interest (ROI). Each region of interest (ROI) contains one or more different object lesions (OL) and is specified in inspection data (21) containing one or more inspection images (19), and is specified so as to contain an object lesion (OL), which is a lesion existing in an inspection image (19). The individual similarity calculation unit (65) calculates an individual degree of similarity for each region of interest (ROI) by comparing the feature amount for each region of interest (ROI) and the feature amount for a medical case lesion (CL), which is a lesion in a medical case image (22) and registered in a medical case. The similar medical case search unit (67) calculates an integrated degree of similarity on the basis of multiple calculated individual degrees of similarity, and searches for similar medical cases on the basis of the integrated degree of similarity that has been calculated.
Triple negative breast cancers (TNBC) are characterized by a poor prognosis and a lack of targeted treatments. Their progression depends on tumor cell intrinsic factors, the tumor microenvironment and host characteristics. Although adipocytes, the primary stromal cells of the breast, have been determined to be plastic in physiology and cancer, the tumor-derived molecular mediators of tumor-adipocyte crosstalk have not been identified yet. In this study, we report that the crosstalk between TNBC cells and adipocytes in vitro beyond adipocyte dedifferentiation, induces a unique transcriptional profile that is characterized by inflammation and pathways that are related to interaction with the tumor microenvironment. Accordingly, increased cancer stem-like features and recruitment of pro-tumorigenic immune cells are induced by this crosstalk through CXCL5 and IL-8 production. We identified serum amyloid A1 (SAA1) as a regulator of the adipocyte reprogramming through CD36 and P2XR7 signaling. In human TNBC, SAA1 expression was associated with cancer-associated adipocyte infiltration, inflammation, stimulated lipolysis, stem-like properties, and a distinct tumor immune microenvironment. Our findings constitute evidence that the interaction between tumor cells and adipocytes through the release of SAA1 is relevant to the aggressiveness of TNBC.
Type 1 diabetes mellitus (T1DM) is T-cell mediated autoimmune disease in which the function of insulin-secreting pancreatic β-cells is impaired due to autoreactive immune cell-mediated destruction (insulitis). Although adaptive immunity has always been the focus for scientists in studying the pathogenesis of T1DM, yet, innate immunity also plays a critical role. Alterations in innate immune responses drive autoimmune pathogenesis, with involvement in the initial break in tolerance and the later failure of regulation. Several studies suggest that the development of T1DM is strongly associated with different immune cells, including monocytes. Specifically, an increase in the monocyte population has been shown to trigger β-cell destruction during insulitis. Intermediate monocytes may serve as M2 macrophage precursors with high anti-inflammatory properties, producing IL-10. However, other studies reported them to have an antigen-presenting function with a dendritic cell-like feature. Upon antigen stimulation, they became the main producers of inflammatory factors, like TNF-α which has been shown to correlate with the severity of T1DM. Activation of circulating monocytes to a pro-inflammatory state induces the shedding of membrane bound CD14 (mCD14) to soluble CD14. Compared to other acute phase proteins, sCD14 was found to be the most sensitive in T1DM. Soluble CD163 is present in blood serum as a result of shedding the CD163 membrane form of activated monocyte-macrophage-lineage cells in the course of inflammation. Plasma sCD163 is widely used as an immunomodulator with anti-inflammatory properties. It was found to be increased in T2DM.
PURPOSE:A mucosal absorbable diuretic agent containing a mammal atrial sodium diuretic peptide as an active constituent. CONSTITUTION:A mucosal absorbable diuretic agent, containing a mammal atrial sodium diuretic peptide, e.g. human-derived alpha type or rat ANFIV type, as an active constituent and capable of producing effect through the nasal cavity, sublingual or rectal mucosa, etc. Examples of the administration form and pharmaceutical include dropping pipet type drip administration spray type adminsitration as a solution, sublingual tablet, suppository, etc., as a solid pharmaceutical, etc. Since the above-mentioned peptide is soluble in relatively stably in distilled water for injection, the administration into the nasal cavity by the spray method is particularly preferred. A solution containing a medium with little irritancy, e.g. physiological saline solution, added thereto can be used. The dose thereof is 0.1-100mug/kg/time, and can be administered once or several times a day.
BACKGROUND: Chronic hepatitis B (CHB) infection is the leading cause of chronic liver disease in sub-Saharan Africa. A significant proportion of patients with CHB are inactive carriers, for whom guidelines neither recommend biopsy nor treatment. In sub-Saharan Africa, patients under 30 years old with CHB sometimes develop liver cancer, raising the possibility that significant liver disease may occur early in life in these patients.
METHODS: A hospital-based cross-sectional study was conducted on patients with inactive CHB. A convenient sampling method was used to recruit patients. All patients underwent a percutaneous liver biopsy to evaluate significant necroinflammation and fibrosis using the Meta-analysis of histological data in viral hepatitis (METAVIR) system, defined as at least METAVIR A2, F2 disease. Tests of association between the histological outcomes, sociodemographic factors, and laboratory findings were performed. The data obtained were entered into the Statistical Package for the Social Sciences (SPSS) version 21 and analysed using descriptive and inferential statistics. A p-value of < 0.05 was considered statistically significant.
RESULTS: A total of 88 patients-60 males (68.2%) and 28 females (31.8%)-completed the study. The study participants were aged 18 to 29 years, with a mean age of 25.4 ± 3.4 years. Thirty-nine (44.3%) had significant necroinflammation and/or fibrosis on histology, 19 (21.6%) of whom had necroinflammation only, and 13 (14.8%) had both necroinflammation and fibrosis. Males had significant necroinflammation and fibrosis more than the females. A family history of death from liver disease was associated with significant liver fibrosis (p < 0.05).
CONCLUSION: A portion of young patients with inactive CHB have significant liver disease, particularly those with a family history of liver-related death. Liver biopsy may therefore be beneficial in these categories of patients to detect this.
FIELD: food industry, pharmacy. SUBSTANCE: stabilized an aqueous solution has sorbic acid or its salt taken in the amount providing antibacterial effect and a stabilizing agent - a solution of bivalent manganese ion in the amount from 0.1 to 5 mass parts per a million of solution that is sufficient to inhibit sorbic acid or its salt oxidation to acetaldehyde. Stabilized solution exhibits good solubility in a composition and safety in foodstuffs and fungicide effect also. Invention is used as antibacterial agents for packaged food and pharmaceutical products. EFFECT: improved quality of solution and composition. 21 cl, 3 ex, 13 dwg
This is a prospective, single-arm, single-center, post-market, pilot study to collect data on back pain relief, subject satisfaction, quality of life, physical functioning and safety. Chronic discogenic pain(CDP) suffering patients will be followed for 12 months with follow-up visits at 3, 6, and 12 months. In line with standard practice the system will be implanted in two stages. The first stage is the Trial Burst spinal cord Neurostimulation (TBNS) phase during which epidural leads are implanted and temporarily tunnelled to an external trial stimulation device. Subjects will then utilize the temporary system for a period in line with usual practice (typically 10-14 days). If, at the end of this TBNS phase a reduction of ≥50% is achieved the device will be permanently implanted (the second stage) and subjects will be followed-up during 12 months. Patients who do not have at least 50% pain relief during TBNS will receive a Trial Tonic Neurostimulator(TTNS) targeting the dorsal root ganglion(DRG). Similarly, these patients will be followed-up during 12 months.
Squamous cell carcinoma of the head and neck (SCCHN) is a commonly detected cancer worldwide. Human papillomavirus (HPV) is emerging as an important risk factor affecting SCCHN prognosis. Therefore, identification of HPV status is essential for effective therapies in SCCHN. The aim of this study was to investigate the prognostic value of HPV-associated RNA biomarkers for SCCHN. The clinical data, survival data, and RNA-seq data of SCCHN were downloaded from The Cancer Genome Atlas database. Before the differential expression analysis, the heterogeneity between the 2 groups (HPV+ vs HPV-) of samples was analyzed using principal component analysis. The differentially expressed genes (DEGs) between HPV+ and HPV- SCCHN samples were analyzed using the R edgeR package. The Gene Ontology functional annotations, including biological process, molecular function and cellular component (CC), and Kyoto Encyclopedia of Genes And Genomes pathways enriched by the DEGs were analyzed using DAVID. The obtained matrix was analyzed by weighed gene coexpression network analysis. A total of 350 significant DEGs were identified through differential analysis, and these DEGs were significantly enriched in functions associated with keratinization, and the pathway of neuroactive ligand-receptor interaction. Moreover, 72 hub genes were identified through weighed gene coexpression network analysis. After the hub genes and DEGs were combined, we obtained 422 union genes, including 65 survival-associated genes. After regression analysis, a HPV-related prognostic model was established, which consisted of 8 genes, including Clorf105, CGA, CHRNA2, CRIP3, CTAG2, ENPP6, NEFH, and RNF212. The obtained regression model could be expressed by an equation as follows: risk score = 0.065 × Clorf105 + 0.012 × CGA + 0.01 × CHRNA2 + 0.047 × CRIP3 + 0.043 × CTAG2-0.034 × ENPP6 - 0.003 × NEFH - 0.068 × RNF212. CGA interacted with 3 drugs, and CHRNA2 interacted with 11 drugs. We have identified an 8 HPV-RNA signature associated with the prognosis of SCCHN patients. Such prognostic model might serve as possible candidate biomarker and therapeutic target for SCCHN.
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution; however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
Treatment P-Gemox dosages were as follows: days 1, 30 min intravenous infusion of 1250 mg/m2 gemcitabine; day 1, 2h intravenous infusion of 85 mg/m2 oxaliplatin; day 1, deep intramuscular injection of 2500 U/m2 PEG-ASP at three different sites. The regimen was repeated every 2 weeks for a maximum of six cycles. Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy. Stage IIIE/IVE patients patients underwent at least two cycles treatments unless there was disease progression or unacceptable side effects, or withdrawal of patient consent. Primary tumor radiotherapy was recommended after they achieved CR.
This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
<P>PROBLEM TO BE SOLVED: To provide a dried bean-curd sheet ensured to make the best use of the properties inherent in dried bean-curd despite being thin and in a sheet form, also enabling its long-term storage at individual home, and easily applicable to the face so as not to be broken or get out of shape in its use.  <P>SOLUTION: The dried bean-curd sheet is provided through the following steps: A sheet-like raw dried bean-curd is formed circularly corresponding to the face, and cuts and cutouts corresponding to the eyes, nose and mouth are formed into a processed dried bean-curd sheet. For the shape maintenance of the processed dried bean-curd sheet and the freeze-storage of a plurality of the sheets mutually superimposed, at least one side of the processed dried bean-curd sheet is stuck with a filmy support member. Thereby, in particular, the dried bean-curd sheet is configured to be used for face pack without getting out of shape despite being thin and fragile and susceptible to be broken, owing to the presence of a substrate member. Thus, the dried bean-curd sheet is easy to handle, storable for a long period as a frozen product, and also usable by separating one sheet each from a multiply superimposed state.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation. In 2-year placebo-controlled trials in adult patients, the reduction from baseline in the percent of predicted values for FEV1 at the time of last assessment on drug was 2.8% for GILENYA 0.5 mg and 1.0% for placebo. For DLCO, the reduction from baseline in percent of predicted values at the time of last assessment on drug was 3.3% for GILENYA 0.5 mg and 0.5% for placebo. The changes in FEV1 appear to be reversible after treatment discontinuation. There is insufficient information to determine the reversibility of the decrease of DLCO after drug discontinuation. In MS placebo-controlled trials in adult patients, dyspnea was reported in 9% of patients receiving GILENYA 0.5 mg and 7% of patients receiving placebo. Several patients discontinued GILENYA because of unexplained dyspnea during the extension (uncontrolled) studies. GILENYA has not been tested in MS patients with compromised respiratory function.

Spirometric evaluation of respiratory function and evaluation of DLCO should be performed during therapy with GILENYA if clinically indicated.
Myasthenia gravis (MG) has been described as a great mimicker of other neurologic and ocular motility disorders, including centrally mediated ophthalmoplegia. For example, ocular myasthenia gravis (ocular MG) may cause impaired binocular visual acuity for near vision due to reduced accommodation or for distance vision due to accommodative excess. Notably, accommodative excess due to ocular MG is rare, but may occur with exotropia, with or without diplopia. We report 2 cases of ocular MG: First, a 32-year-old man with exotropia, bilateral hypometric and slowed adducting saccades with dissociated abducting nystagmus, miosis, and decreased distance vision in his right eye; second, a 45-year-old man with similar ocular motor deficits, miosis, and myopia. Both patients showed ocular motor deficits which appeared to localize to the pons but were instead due to ocular MG. Ocular MG should be considered in patients who present with reduced visual acuities due to any disruption in accommodation. Any ocular motor deficit, even if appearing to be centrally mediated or occurring without ptosis, may be caused by ocular MG.
Chronic rhinosinusitis (CRS) represents a heterogeneous disorder primarily characterized by the persistent inflammation of the nasal cavity and paranasal sinuses. The subtype known as chronic rhinosinusitis with nasal polyposis (CRSwNP) is distinguished by a significantly elevated recurrence rate and augmented challenges in the management of nasal polyps. The pathogenesis underlying this subtype remains incompletely understood. Macrophages play a crucial role in mediating the immune system's response to inflammatory stimuli. These cells exhibit remarkable plasticity and heterogeneity, differentiating into either the pro-inflammatory M1 phenotype or the anti-inflammatory and reparative M2 phenotype depending on the surrounding microenvironment. In CRSwNP, macrophages demonstrate reduced production of Interleukin 10 (IL-10), compromised phagocytic activity, and decreased autophagy. Dysregulation of pro-resolving mediators may occur during the inflammatory resolution process, which could potentially hinder the adequate functioning of anti-inflammatory macrophages in facilitating resolution. Collectively, these factors may contribute to the prolonged inflammation observed in CRSwNP. Additionally, macrophages may enhance fibrin cross-linking through the release of factor XIII-A (FAXIII), promoting fibrin deposition and plasma protein retention. Macrophages also modulate vascular permeability by releasing Vascular endothelial growth factor (VEGF). Moreover, they may disrupt the balance between Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs), which favors extracellular matrix (ECM) degradation, edema formation, and pseudocyst development. Accumulating evidence suggests a close association between macrophage infiltration and CRSwNP; however, the precise mechanisms underlying this relationship warrant further investigation. In different subtypes of CRSwNP, different macrophage phenotypic aggregations trigger different types of inflammatory features. Increasing evidence suggests that macrophage infiltration is closely associated with CRSwNP, but the mechanism and the relationship between macrophage typing and CRSwNP endophenotyping remain to be further explored. This review discusses the role of different types of macrophages in the pathogenesis of different types of CRSwNP and their contribution to polyp formation, in the hope that a better understanding of the role of macrophages in specific CRSwNP will contribute to a precise and individualized understanding of the disease.
Recent evidence suggests that systemic conditions, particularly those associated with inflammation, can affect erythrocyte deformability in the absence of haematological conditions. In this exploratory study, we investigated the relationship between systemic inflammatory status and erythrocyte deformability (using osmotic gradient ektacytometry) in a heterogenous study population consisting of individuals with no medical concerns, chronic conditions, and acute illness, providing a wide range of systemic inflammation severity. 22 participants were included in a prospective observational study. Maximum Elongation Index (EImax) in ektacytometry served as the readout for erythrocyte deformability. Inflammatory status was assessed using C-reactive protein (CRP) and self-reported symptoms associated with inflammatory activation (Sickness Questionnaire Scores, SicknessQ). In a univariate linear regression, both CRP and SicknessQ scores significantly predicted EImax (CRP: F(1,20) = 7.751, p < 0.05 (0.011), R2 = 0.279; SicknessQ: F(1,18) = 4.831, p < 0.05 (0.041), R2 = 0.212). Sensitivity analyses with multivariable linear regression correcting for age showed concordant findings. Results suggest a linear relationship between erythrocyte deformability and biochemical and clinical markers of systemic inflammation. Replication of findings in a larger study, and mechanisms and clinical consequences need further in investigation.